Abstract: The present invention generally relates to broad-spectrum antiviral compounds that can be used as preventive and/or therapeutic antiviral medicine; pharmaceutical compositions or combinations comprising such compounds; and compounds or pharmaceutical compositions or combinations for use in the treatment (e.g., for preventive and/or therapeutic use) of viral infections.

Abstract: The present invention relates to novel compounds which are particularly useful as inhibitors of bacterial glutaminyl cyclases (bacQC); pharmaceutical compositions comprising such compounds; compounds and/or pharmaceutical compositions for use in methods for treatment, in particular for use in the treatment of periodontitis and related conditions; as well as to crystals comprising bacterial glutaminyl cyclases, methods for identifying candidate compounds which may associate with the binding pocket of a bacQC and/or are bacQC inhibitors.

Abstract: The present invention relates to a peptide with a length of 25 amino acids or less comprising the sequence X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (SEQ ID No: 1) as well as to A peptide with a length of 25 amino acids or less comprising the sequence X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14 (SEQ ID No: 2). The present invention further relates to a nanostructure comprising a nucleic acid scaffold and at least two peptide moieties, wherein the sequence of each of the at least two peptide moieties is independently selected from the sequence of the peptide of the invention as well as pharmaceutical compositions, nucleic acids, methods and uses related thereto.

Abstract: The present invention relates to novel compounds which are particularly useful as inhibitors of bacterial glutaminyl cyclases (bacQC); pharmaceutical compositions comprising such compounds; compounds and/or pharmaceutical compositions for use in methods for treatment, in particular for use in the treatment of periodontitis and related conditions; as well as to crystals comprising bacterial glutaminyl cyclases, methods for identifying candidate compounds which may associate with the binding pocket of a bacQC and/or are bacQC inhibitors.

Abstract: A gas concentration-measuring device makes it possible to measure gas components in a gas sample. An interferometer, based on a dual-band Fabry-Perot interferometer (1), is provided with a transmission spectrum that can be set by a control voltage (38). The control voltage (38) of the dual-band Fabry-Perot interferometer (1) is synchronized over the course of time with the activation and deactivation of the radiation sources (11, 12).

Abstract: The present invention relates to an X-ray amorphous-crystalline material with high solubility which can be used as a bioactive bone replacement material and as a substrate material in biotechnology. The new material comprising crystalline and X-ray amorphous phases is characterized in that according to 31P-NMR measurements, it contains Q0-groups of orthophosphate and Q1-groups of diphosphate, the orthophosphates or Q0-groups making up 70 to 99.9% by weight relative to the total phosphorus content of the finished material and the diphosphates or Q1-groups making up 0.1 to 30% by weight relative to the total phosphorus content of the finished material, and that according to X-ray diffractometric measurements and relative to the total weight of the finished material, 30 to 99.9% by weight of a main crystal phase consisting of Ca2K1?xNa1+x(PO4)2, where x=0.1 to 0.9, is contained in the bone replacement material and 0.

Abstract: A gas concentration-measuring device makes it possible to measure gas components in a gas sample. An interferometer, based on a dual-band Fabry-Perot interferometer (1), is provided with a transmission spectrum that can be set by a control voltage (38). The control voltage (38) of the dual-band Fabry-Perot interferometer (1) is synchronized over the course of time with the activation and deactivation of the radiation sources (11, 12).

Abstract: The present invention relates to an X-ray amorphous-crystalline material with high solubility which can be used as a bioactive bone replacement material and as a substrate material in biotechnology. The new material comprising crystalline and X-ray amorphous phases is characterized in that according to 31P-NMR measurements, it contains Q0-groups of orthophosphate and Q1-groups of diphosphate, the ortho-phosphates or Q0-groups making up 70 to 99.9% by weight relative to the total phosphorus content of the finished material and the diphosphates or Q1-groups making up 0.1 to 30% by weight relative to the total phosphorus content of the finished material, and that according to X-ray diffractometric measurements and relative to the total weight of the finished material, 30 to 99.9% by weight of a main crystal phase consisting of Ca2K1?xNa1+x(PO4)2, where x=0.1 to 0.9, is contained in the bone replacement material and 0.

Abstract: The present invention relates to an X-ray amorphous-crystalline material with high solubility which can be used as a bioactive bone replacement material and as a substrate material in biotechnology. The new material comprising crystalline and X-ray amorphous phases is characterized in that according to 31P-NMR measurements, it contains Q0-groups of orthophosphate and Q1-groups of diphosphate, the ortho-phosphates or Q0-groups making up 70 to 99.9% by weight relative to the total phosphorus content of the finished material and the diphosphates or Q1-groups making up 0.1 to 30% by weight relative to the total phosphorus content of the finished material, and that according to X-ray diffractometric measurements and relative to the total weight of the finished material, 30 to 99.9% by weight of a main crystal phase consisting of Ca2K1?xNa1+x(PO4)2, where x=0.1 to 0.9, is contained in the bone replacement material and 0.

Abstract: The present invention relates to a material with orthophosphate and having a high solubility which can be used as a bioactive bone replacement material and as a substrate material in biotechnology. According to 31P-NMR measurements, the new material comprises Q0-groups of orthophosphate and Q1-groups of diphosphate, the orthophosphates or Q0-groups making up 65 to 99.9% by weight relative to the total phosphorus content of the finished material and the diphosphates or Q1-groups making up 0.1 to 35% by weight relative to the total phosphorus content of the finished material, and wherein according to X-ray diffractometric measurements and relative to the total weight of the finished material, 35 to 99.9% by weight of a main crystal phase consisting of Ca10Na(PO4)7, Ca10K(PO4)7, mixtures thereof or mixed crystals according to the general formula Ca10KxNa1?x(PO4)7, where x=0 to 1, is contained in the bone replacement material and 0.

Abstract: The present invention relates to a powder mixture for resorbable calcium phosphate biocements, which mixture consists of 40–99% by volume of powder having a particle size of 0.1–10 ?m, 1–20% by volume of powder having a particle size of 10–43 ?m and 0–59% by volume of powder having a particle size of 43–315 ?m, which powder is obtained by grinding the spontaneously crystallizing melts of a material comprising crystalline and X-ray amorphous phases, which material a) according to 31P-NMR measurements, contains Q0-groups of orthophosphate and Q1-groups of diphosphate, the orthophosphates or Q0-groups making up 65 to 99.9% by weight relative to the total phosphorus content of the powder mixture and the diphosphates or Q1-groups making up 0.1 to 35% by weight relative to the total phosphorus content of the powder mixture, and b) according to X-ray diffractometric measurements and relative to the total weight of the powder mixture, contains 35 to 99.

Abstract: The present invention relates to an X-ray amorphous-crystalline material with high solubility which can be used as a bioactive bone replacement material and as a substrate material in biotechnology. The new material comprising crystalline and X-ray amorphous phases is characterized in that according to 31P-NMR measurements, it contains Q0-groups of orthophosphate and Q1-groups of diphosphate, the ortho-phosphates or Q0-groups making up 70 to 99.9% by weight relative to the total phosphorus content of the finished material and the diphosphates or Q1-groups making up 0.1 to 30% by weight relative to the total phosphorus content of the finished material, and that according to X-ray diffractometric measurements and relative to the total weight of the finished material, 30 to 99.9% by weight of a main crystal phase consisting of Ca2K1−xNa1+x(PO4)2, where x=0.1 to 0.9, is contained in the bone replacement material and 0.

Abstract: The present invention relates to a material with orthophosphate and having a high solubility which can be used as a bioactive bone replacement material and as a substrate material in biotechnology. According to 31P-NMR measurements, the new material comprises Q0-groups of orthophosphate and Q1-groups of diphosphate, the ortho-phosphates or Q0-groups making up 65 to 99.9% by weight relative to the total phosphorus content of the finished material and the diphosphates or Q1-groups making up 0.1 to 35% by weight relative to the total phosphorus content of the finished material, and wherein according to X-ray diffractometric measurements and relative to the total weight of the finished material, 35 to 99.9% by weight of a main crystal phase consisting of Ca10Na(PO4)7, Ca10K(PO4)7, mixtures thereof or mixed crystals according to the general formula Ca10KxNa1−x(PO4)7, where x=0 to 1, is contained in the bone replacement material and 0.

Abstract: The present invention relates to a powder mixture for resorbable calcium phosphate biocements, which mixture consists of 40-99% by volume of powder having a particle size of 0.

Abstract: A plate-like water aerator is provided. A plate, made of elastomeric material, is disposed on a rigid, essentially planar mounting support and covers the one or more air supply connections thereof. The plate is provided with fine slits for the discharge of air. The mounting support has a circumferential rim that is angled-off at substantially right angles. The mounting support also has a circumferential rib that extends parallel to the rim in such a way as to form a circumferential groove between the rib and the rim. The plate has an essentially u-shaped rim portion, a radially inwardly disposed leg of which surrounds the rim of the mounting support and engages in the circumferential groove in a manner free of play.

Abstract: A headlamp for motor vehicles has a reflector, a gas discharge lamp, a front plate covering a light exit opening of the headlamp, and a filter arranged in a beam path of light beams reflected by the reflector and light beams transmitted directly to the front plate and at least partially absorbing light in a UV wavelength region.